GspA Peptide Stimulates GLP-1 Secretion for Metabolic Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for obesity and diabetes, particularly type 2 diabetes, often fail to effectively increase insulin sensitivity, reduce glucose production in the liver, and suppress appetite, leading to suboptimal management of metabolic disorders.
Innovation Solution
A peptide, GspA, derived from Staphylococcus epidermidis, is used to enhance GLP-1 secretion, which increases insulin sensitivity, reduces glucose production, suppresses appetite, and improves beta cell mass in the pancreas, thereby treating or preventing obesity and diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for obesity and diabetes are used, then they provide some therapeutic effect, but they fail to effectively increase insulin sensitivity, reduce glucose production in the liver, and suppress appetite
Solution Approach 1:
The patent uses GLP-1 as an intermediary substance that mediates between the administered peptide (GspA) and the target metabolic processes. The peptide GspA stimulates endogenous GLP-1 secretion, which then acts as the active mediator to improve insulin sensitivity, reduce hepatic glucose production, and suppress appetite, thereby resolving the contradiction between current treatment reliability and desired therapeutic productivity
2Reliability
If current treatments for obesity and diabetes are used, then they provide some therapeutic effect, but they fail to effectively reduce glucose production in the liver
Solution Approach 1:
GLP-1 serves as the intermediary that transmits the therapeutic effect from the administered peptide to the liver's glucose production pathways. The peptide GspA indirectly reduces hepatic glucose production by stimulating GLP-1 secretion, which then acts on glucagon-secreting cells to inhibit excessive glucose output, resolving the contradiction between general therapeutic effect and specific glucose production reduction
3Reliability
If current treatments for obesity and diabetes are used, then they provide some therapeutic effect, but they fail to effectively suppress appetite
Solution Approach 1:
GLP-1 acts as the intermediary substance that carries out the appetite suppression function. The administered peptide GspA stimulates GLP-1 secretion from L-cells, and the increased GLP-1 levels then act on hypothalamic receptors to suppress appetite and promote satiety, resolving the contradiction between overall therapeutic effect and specific appetite control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
GspA effectively increases GLP-1 levels, reducing body mass, adiposity, glycemia, and improving insulin sensitivity, demonstrating therapeutic benefits in managing obesity and diabetes by stimulating GLP-1 production and secretion.
Implementation Method 1
GLP-1 is an incretin hormone produced by a subset of enteroendocrine cells in the gut epithelium. The present work demonstrates that a peptide, termed GspA, can enhance GLP-1 secretion
Data Source
AI summary
Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.